Bioniche Life Sciences and Endo Pharmaceuticals Sign Licensing Agreement

On July 9, 2009, Bioniche Life Sciences Inc., the publicly listed Canadian biopharmaceutical company and its wholly owned subsidiary Bioniche Urology Inc. (collectively Bioniche), entered into a US licence, development and supply agreement with Endo Pharmaceuticals Inc. concerning its lead drug candidate Urocidin™. The deal includes an option for global rights and calls for an up-front cash payment of US$20 million to Bioniche with the potential for up to US$110 million in additional payments based on clinical, regulatory and commercial milestones.

Urocidin™ is a formulation of Mycobacterial Cell Wall-DNA Complex for the treatment of bladder cancer that is in Phase III clinical program with the US Food and Drug Administration.

Bioniche was represented by Ogilvy Renault LLP with a team that included Richard Sutin and Jeremy Grushcow.

Endo Pharmaceuticals was represented in-house by Douglas D. Macpherson, vice president and associate general counsel, with external assistance provided by Drinker Biddle & Reath LLP with a team that included Neil Haimm and Justin Watkins.